Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes ( SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Aim: To compare the efficacy and safety of once‐weekly (OW) semaglutide versus thrice‐daily (TID) insulin aspart (IAsp) in participants with inadequately controlled type 2 diabetes (T2D) treated with insulin glargine (IGlar) and metformin. Materials and Methods: SUSTAIN 11 (NCT03689374) was a randomized (1:1), parallel, open‐label, multinational, phase 3b trial. After a 12‐week run‐in to optimize once‐daily IGlar U100, 1748 adults with T2D (HbA1c >7.5% to ≤10.0%) were randomized to OW semaglutide or TID IAsp as add‐on to optimized IGlar and metformin for 52 weeks. The primary outcome was change in HbA1c from randomization to week 52. Confirmatory secondary endpoints included the occurrence of severe hypoglycaemic episodes and change in body weight (BW). Safety was assessed. Results: HbA1c (randomization: 8.6% [70.0 mmol/mol]) decreased by 1.5% points (16.6 mmol/mol) and 1.2% points (13.4 mmol/mol) with semaglutide (n = 874) and IAsp (n = 874), respectively (estimated treatment difference [ETD] −0.29% points [95% confidence interval {CI} −0.38; −0.20]; P < .0001 for non‐inferiority). Few severe hypoglycaemic episodes were recorded in either group, with no statistically significant difference between the groups. Change in BW from randomization (87.9 kg) to week 52 was in favour of semaglutide (−4.1 kg) versus IAsp (+2.8 kg) (ETD −6.99 kg [95% CI −7.41; −6.57]). A higher proportion of participants experienced adverse events with semaglutide (58.5%) versus IAsp (52.1%); most were mild to moderate. Conclusions: In this basal insulin‐treated population, OW semaglutide improved glycaemic control to a greater extent than TID IAsp and provided numerically greater weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 4×
“The safety profile of OW semaglutide in this trial was determined to be consistent with its wellestablished safety profile and consistent with the GLP-1RA drug class in general.(13-22) Participants enrolled in this trial were slightly older than other SUSTAIN trial populations, had longer diabetes duration and latesta…”
BackgroundResultInfluentialAhmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495 · cited 4×
“The safety profile of OW semaglutide in this trial was determined to be consistent with its wellestablished safety profile and consistent with the GLP-1RA drug class in general.(13-22) Participants enrolled in this trial were slightly older than other SUSTAIN trial populations, had longer diabetes duration and latesta…”
BackgroundResultInfluentialBuse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05039-w · Cited by 487
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · cited 1×
“This reflects the known effects of GLP-1RAs and insulins on BW previously shown in other randomized clinical trials, with GLP-1RAs associated with weight loss and insulins with weight gain.(16,34,35) In our study, decreases in systolic blood pressure were observed with semaglutide, in accordance with previous studies…”
ResultSemaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412 · cited 4×
“The safety profile of OW semaglutide in this trial was determined to be consistent with its wellestablished safety profile and consistent with the GLP-1RA drug class in general.(13-22) Participants enrolled in this trial were slightly older than other SUSTAIN trial populations, had longer diabetes duration and latesta…”
BackgroundResultInfluentialSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4127 · Cited by 412
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · cited 4×
“The safety profile of OW semaglutide in this trial was determined to be consistent with its wellestablished safety profile and consistent with the GLP-1RA drug class in general.(13-22) Participants enrolled in this trial were slightly older than other SUSTAIN trial populations, had longer diabetes duration and latesta…”
BackgroundResultInfluentialGiorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268 · cited 1×
“This reflects the known effects of GLP-1RAs and insulins on BW previously shown in other randomized clinical trials, with GLP-1RAs associated with weight loss and insulins with weight gain.(16,34,35) In our study, decreases in systolic blood pressure were observed with semaglutide, in accordance with previous studies…”
ResultHusain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209 · cited 4×
“Goals include minimizing hypoglycaemia and weight gain, and reducing the risk of complications such as atherosclerotic cardiovascular (CV) disease.1,2 While some clinical guidelines recommend a glucagon-like peptide-1 receptor agonist (GLP-1RA) as the first injectable antihyperglycaemic during treatment intensificatio…”
BackgroundInfluentialDifferential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Castellana, M., Cignarelli, A., Brescia, F., Laviola, L., & Giorgino, F. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3082 · Cited by 84
Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care · doi:10.2337/dc19-2316 · Cited by 73
Rajamand Ekberg, N., Bodholdt, U., Catarig, A.-M., Catrina, S.-B., Grau, K., Holmberg, C. N., Klanger, B., & Knudsen, S. T. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2021.06.008 · Cited by 63
Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study
Patel, S., Abreu, M., Tumyan, A., Adams-Huet, B., Li, X., & Lingvay, I. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000761 · Cited by 56 · cited 6×
“Goals include minimizing hypoglycaemia and weight gain, and reducing the risk of complications such as atherosclerotic cardiovascular (CV) disease.1,2 While some clinical guidelines recommend a glucagon-like peptide-1 receptor agonist (GLP-1RA) as the first injectable antihyperglycaemic during treatment intensificatio…”
BackgroundResultInfluentialRudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108931 · Cited by 46
Holmes, P., Bell, H. E., Bozkurt, K., Catarig, A.-M., Clark, A., Machell, A., & Sathyapalan, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01141-8 · Cited by 42 · cited 1×
“An imbalance in AEs with fatal outcome was observed with semaglutide versus IAsp, which contrasts with previous, extensive data with OW semaglutide from clinical trials,(13-22) including the CVOT SUSTAIN 6(22) and real-world data.(38-41) There was no clustering of causes or any observed pattern regarding the timing of…”
ResultWitkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D., & Vrazic, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0428-y · Cited by 18
Cited by
Rosenstock, J., Frías, J. P., Rodbard, H. W., Tofé, S., Sears, E., Huh, R., Fernández Landó, L., & Patel, H. (2023) · JAMA · doi:10.1001/jama.2023.20294 · Cited by 156
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06144-1 · Cited by 102
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Feier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084346 · Cited by 60
“Similarly, the SUSTAIN and STEP series, including trials such as SUSTAIN 11 by Kellerer M et al. [47] and STEP TEENS by Weghuber D et al. [41], were not considered, as they either overlapped with included studies or did not report on this review’s primary outcomes.”
MethodResultThe effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Metadata
- Authors
- Kellerer, M., Kaltoft, M. S., Lawson, J., Nielsen, L. L., Strojek, K., Tabak, Ö., & Jacob, S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2022-06-29
- Volume
- 24
- Issue
- 9
- Pages
- 1788-1799
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4280597148
- Cited by
- 86
- References
- 22
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.